S100A8 is a Novel Therapeutic Target for Anaplastic Thyroid Carcinoma | Zendy

Ashley N. Reeb | Zendy; Wen Li | Zendy; Will Sewell | Zendy; Laura A. Marlow | Zendy; Han W. Tun | Zendy; Robert C. Smallridge | Zendy; John A. Copland | Zendy; Kyle Spradling | Zendy; Rebecca D. Chernock | Zendy; Reigh-Yi Lin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

S100A8 is a Novel Therapeutic Target for Anaplastic Thyroid Carcinoma

Author(s) -

Ashley N. Reeb,

Wen Li,

Will Sewell,

Laura A. Marlow,

Han W. Tun,

Robert C. Smallridge,

John A. Copland,

Kyle Spradling,

Rebecca D. Chernock,

Reigh-Yi Lin

Publication year - 2014

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2014-2988

Subject(s) - cancer research , gene knockdown , s100a9 , thyroid carcinoma , s100a8 , anaplastic thyroid cancer , metastasis , biology , lung cancer , cell growth , carcinogenesis , cancer , medicine , thyroid cancer , cell culture , pathology , immunology , thyroid , endocrinology , inflammation , genetics

Anaplastic thyroid carcinoma (ATC) is one of the most deadly human malignancies. It is 99% lethal, and patients have a median survival of only 6 months after diagnosis. Despite these grim statistics, the mechanism underlying the tumorigenic capability of ATC cells is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research